Publications found:
253,269
Sort by:
Mixed CARE-MS I data – Good for BIIB!
US$ 90.00
... (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players ... ? Please read our report, released on 11th July, 2011, titled – “Mixed CARE-MS I data – Good for BIIB!”
July 2011
4 pages
Circulating Tumor Cells (CTCs) Market Trends 2011
US$ 1,589.00
This is the latest and most up-to-date Market Report from Select Biosciences addressing the circulating tumor cells (CTCs) space. In this report, we focus upon the emerging marketplace for the isolation and study of CTCs, a potentially important tool for cancer diagnostics with special relevance to ...
June 2011
89 pages
Mirabegron Gets JP Approval – Expecting US Filing & Approval In Time!
US$ 90.00
... rating on Astellas following announcement of JP approval for Betanis / mirabegron (β3-AR agonist, overactive bladder syndrome (OAB). Mirabegron is a key strategic product for ... able to maintain its leadership in the growing OAB market. Mirabegron will be targeted for those patients who are intolerant to ...
June 2011
4 pages
Para IV Pipeline Analysis of Indian Pharma Companies
US$ 400.00
... cliff of 2014, many of the Indian companies are choosing the Para IV route to grab a higher market share, both in value and volume ... world’s top 11 products under litigation. This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the ...
June 2011
214 pages
NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
US$ 90.00
... daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE’s Spiriva (once ... antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately ...
June 2011
2 pages
Eliquis (Apixaban) meets endpoints in ARISTOTLE - Stock Price Reaction premature
US$ 140.00
... from the ARISTOTLE trial, Eliquis met both, the primary (reduction in stroke and embolism) and secondary endpoint (reduction in major bleeding and ... stock price reaction is a bit premature, as detailed data is crucial to understand Eliquis relative efficacy/safety compared to Pradaxa and Xarelto. From a trial ...
June 2011
3 pages
REGENERON, Outperform - Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout
US$ 90.00
... ) or colchicine primarily on safety concerns. Based on our analysis, we reiterate our Outperform rating on Regeneron (REGN) with a revised TP of $62 (vs. previous $65) as we believe both these drugs ... read our report released on 23rd June, 2011 on REGN named “Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout”.
June 2011
5 pages
Asia Pacific Biotechnology Market (2008-2012)
US$ 1,600.00
Single User PDF Format: US$ 1,600.00 Multi-User License: US$ 2,400.00 Hard Copy: US$ 1,800.00 CD-ROM: US$ 1,800.00The Asia Pacific biotechnology market is one with immense potential, which can be tap...
June 2011
165 pages
World Market for Dialysis Equipment and Services
US$ 3,500.00
Prices: Single User PDF: US$ 3,500.00 Departmental Site License (one location, up to 10 users): US$ 5,250.00 Global Site License: US$ 7,000.00 This report looks at both the equipment and service asp...
June 2011
180 pages
World Wound Care Markets 2011
US$ 2,995.00
Prices: Single User PDF: US$ 2,995.00 Departmental Site License (one location, up to 10 users): US$ 4,400.00 Global Site License: US$ 5,990.00 The wound care industry is an highly diverse and compet...
June 2011
175 pages
Indian Diagnostic Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1400.00 Hard Copy: US$ 1000.00 CD-ROM: US$ 1000.00Indian diagnostics sector is witnessing an era of immense progress in innovative competenc...
June 2011
65 pages
Global Obesity Drug Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 1,100.00 CD-ROM: US$ 1,100.00 The obesity epidemic has been disseminating among developed countries as well as low...
June 2011
85 pages
Israel Life Sciences Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 The field of life sciences has stipulated itself as one of the major businesses in Israel....
June 2011
55 pages
MSL-KOL Engagement: Ensuring Compliance
US$ 495.00
After its initial function to build rapport with KOLs, the MSL role has evolved from being a support to sales reps to the forefront of pharmaceutical practice. Lode Dewulf, chief medical affairs offic...
June 2011
47 pages
Pharma on Twitter: Developing a Presence
US$ 395.00
Does your company have a Twitter account? Want to know what all the buzz is about? Whether you are an experienced Twitter user or just curious, Pharma on Twitter: Developing a Presence, shares first-h...
June 2011
56 pages
European Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011
US$ 11,495.00
The combined European cosmetic surgery, facial aesthetics and medical laser device market was valued at over €657 million in 2010. This market ... market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios. This is an executive summary only. The ...
June 2011
287 pages
European Markets for Cardiac Surgery Devices
US$ 11,495.00
... countries covered in this report include: Germany France U.K Italy Spain Benelux Scandinavia Portugal Austria Switzerland Within the European cardiac surgery device market, companies such as Edwards Lifesciences, Maquet, Medtronic, Sorin and St. Jude lead the market, among many others. This ...
June 2011
530 pages
European Markets for Hearing Aids and Audiology Devices 2011
US$ 11,495.00
... models. In addition, the European market for hearing devices exhibits high market potential as the penetration of hearing aid users in Europe is only 18.5%. Growth ... innovations that are offered by the manufacturers and the distribution of hearing aids by the retailers to the end users. This report includes a ...
June 2011
553 pages
What Consumers Want – Buying Trends in European Home Care
US$ 2,000.00
... consumer purchasing patterns today and in the future. Euromonitor International's What Consumers Want – Buying Trends in European Home Care global briefing offers an ... and forecasts), company shares, brand shares and distribution data. Why buy this report? Get a detailed picture of the Home Care market; ...
June 2011
43 pages
Molecular Diagnostics Market Report: 2011 Edition
US$ 800.00
... , QIAGEN, Bayer, Abbott, and Becton Dickinson. The current report analyzes the molecular diagnostic market on the global basis. It also presents a view of the various ...
June 2011
43 pages
Global Wound Care Market Report: 2011 Edition
US$ 700.00
... reliability, price, and global reach, among such other factors. The report offers an analysis of the global wound care market. It also discusses key market trends, growth drivers ...
June 2011
34 pages
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
US$ 660.00
... other pathywas such as the PI3K-Akt-mTOR pathways. Combining a mutant B-Raf inhibitor with a targeted T-cell antibody, such as ipilimumab, may increase ... ERK Pathway Corporate Ras-Raf-MEK-ERK Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers ...
June 2011
75 pages
Analyzing the Major Pharmaceutical Markets
US$ 300.00
... the knowledge employment ratios globally. Aruvian's R'search’s report – Analyzing the Major Pharmaceutical Markets - globally is a complete ready country reckoner which offers the analyst ...
June 2011
100 pages
Looking at Offshoring in the Pharmaceutical Industry
US$ 300.00
... expand their global pharmaceutical revenues. Aruvian's R'search’s report – Looking at Offshoring in the Pharmaceutical Industry - is a detailed analysis of the ... employment scenarios in emerging and growing economies. The impact of Offshoring as a practice cannot be understood without a complete study of ...
June 2011
50 pages
Looking at the Cancer Therapy Market
US$ 200.00
... presents a comprehensive research report – Looking at the Cancer Therapy Market – which analyzes the global cancer market. Explaining the basics of cancer, to the treatments available and ...
June 2011
60 pages
Competitor Analysis: Hepatitis Vaccines
US$ 498.00
... Vaccines Combination Vaccines including HAV Vaccines Combination Vaccines including HBV Vaccines Hepatitis C Virus Vaccines Hepatitis E Virus Vaccines Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...
June 2011
96 pages
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
US$ 711.00
... effort has gone into developing agents that inhibit one or more PI3K isoforms, e.g. alpha and beta, as well as closely related proteins implicated in ... Others Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...
June 2011
100 pages
Competitor Analysis: IGF-1R Antagonists
US$ 275.00
... -1/R antagonists Small Molecule Multi-target IGF-1/R antagonists Biologics as Selective IGF-1/R antagonists Biologics as Dual IGF-1/R antagonists Corporate IGF-1R Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
June 2011
26 pages
INTERCELL - No Tangible Value!
US$ 90.00
... on sideline, as there is no catalyst in 2011-12 that could boost the stock. Intercell (ICLL) woes of 2010 became worse in 2011 chiefly due to the ...
June 2011
1 pages
Catalysts Driven Investment Opportunities
US$ 140.00
... ) in the Biotech sector. The table lists the drug related catalysts for the Rising Star or Mature Biotech companies, our expectations ... of the series, which we will keep releasing in a timely manner. The catalysts include outcome of Advisory Committee Meetings (only June), PDUFA dates ...
June 2011
4 pages
Dr Reddy's PARA IV Pipeline Analysis
US$ 350.00
Dr Reddys has pipeline of ~20 Para IVs having branded sales of ~$24b. Among its Para IV pipeline the confirmed opportunities (branded sales ~$11.2b) are Exelon, Propecia, Zyprexa (20 mg), ... Nexium, Lipitor and Geodon. We expect PAT of ~$185m from the Dr. Reddy’s Para IVs which is ~3% of the current market Cap.
June 2011
21 pages
Lupin's PARA IV Pipeline Analysis
US$ 350.00
Lupin has pipeline of ~34 products having branded sales of ~$16b. Among its Para IV pipeline most lucrative opportunities are very few like that of Geodon, ... and Asacol. On other hand there are some Para IVs ...
June 2011
28 pages
Para IV presentation
US$ 350.00
A macro study on Indian Pharma Para IV litigations – a part of our recently introduced web based application - PARA IV Plus™ . This will provide you with a broad but meaningful insight to the prevalence of Indian Pharmaceutical companies in the Para IV space
June 2011
9 pages
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
Ranbaxy has a pipeline of ~19 Para IV challenges, of which 12 are FTF’s. The total branded sales of these drugs under Para IV challenge by Ranbaxy is approximately $25b. Most of these Para ... offer decent upside. We expect Ranbaxy to generate a cumulative PAT of ~$950m from these Para IV opportunities, which is ...
June 2011
22 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
Emerging Pharmaceutical Markets 2012
US$ 3,907.00
... to strong performance in the emerging pharmaceutical markets, the global pharmaceutical market is expected to reach US$ 1,020 Billion by the end of 2012. This research ... therapeutic segments, different and complex regulatory law and a fragmented market. The worldwide economic crisis has also added a new layer ...
May 2011
222 pages
Umbilical Cord Blood Banking Market Trends 2011
US$ 1,323.00
... , utilization trends of cord blood for different diseases in different countries of the world. This report analyzes the umbilical cord blood marketplace ... and associated qualitative trends. This data-driven characterization of the cord blood banking market landscape is a hands-on document that can be used for ...
May 2011
42 pages
